
Celldex Therapeutics Completes Acquisition of CuraGen Corporation for \$93.5 Million

2009-10-05

On October 1, Celldex Therapeutics, Inc. announced the successful completion of its acquisition of CuraGen Corporation. The purchase price for CuraGen was approximately \$93.5 million and, as a result of the merger, CuraGen has become a wholly owned subsidiary of Celldex. The acquisition adds a portfolio of oncology-focused, fully-owned antibodies to Celldex's Precision Targeted Immunotherapy Platform.

WilmerHale represented CuraGen in this transaction. The WilmerHale team included Lara Mataac and Ravi Faiia from the Corporate Group, and [Kimberly Wethly](#) from the Tax Group. William Schmidt advised on employee benefits, [Sally Byrne](#) advised on licensing and [Michael Twomey](#) advised on patent matters.